Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND
A patient's quality of life is adversely affected by pain. Further, this quality of life is associated with loss of work productivity, which impacts both the patient and its employer adversely.
Thus, for example, moderate to severe pain and physical disability that are symptoms of
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
CROSS REFERENCE TO RELATED APPLICATIONS
This patent application is a U.S. national stage entry under 35 U.S.C. .sctn.371 of International Patent Application No. PCT/JP2012/070902 filed on Aug. 17, 2012, which claims the benefit of foreign priority to Japanese Patent Application No. JP 2011-179134
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to novel heterocyclic derivatives.
BACKGROUND OF THE INVENTION
Prostaglandins (PG) are produced abundantly in the site of inflammation and involved in progress of inflammation. Prostaglandin production is initiated with the release of arachidonic
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
This application is a national stage U.S. application filed under 35 U.S.C. 371 of International application PCT/JP03/00350, filed Jan. 17, 2003, which claimed the priority of Japanese Patent 2002-11914 filed Jan. 21, 2002, the disclosures of which are incorporated herein in its entirety by
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1841/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051096 filed on 10 Feb. 2103, the entire disclosure of which is relied on for all purposes and is incorporated into
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1839/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051089 filed on 10 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1842/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051266 filed on 16 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF INVENTION
This invention relates to nutrition and diet, in particular to novel dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours.
BACKGROUND AND PRIOR ART
Various types of medical
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic
An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht
Oibreacha i 55 teanga
Leigheasanna luibhe le tacaíocht ón eolaíocht
Aitheantas luibheanna de réir íomhá
Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
Léigh foilseacháin eolaíochta a bhaineann le do chuardach
Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní
Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil. * Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe